Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 461

1.

Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis.

Hayashi M, Madokoro H, Yamada K, Nishida H, Morimoto C, Sakamoto M, Yanagawa H, Yamada T.

Cancers (Basel). 2019 Aug 8;11(8). pii: E1138. doi: 10.3390/cancers11081138.

2.

How Does the Recently Discovered Peptide MIP Exhibit Much Higher Binding Affinity than an Anticancer Protein p53 for an Oncoprotein MDM2?

Yamada T, Hayashi T, Hikiri S, Kobayashi N, Yanagawa H, Ikeguchi M, Katahira M, Nagata T, Kinoshita M.

J Chem Inf Model. 2019 Aug 26;59(8):3533-3544. doi: 10.1021/acs.jcim.9b00226. Epub 2019 Jul 18.

PMID:
31282659
3.

Seasonality of i.v. immunoglobulin responsiveness in Kawasaki disease.

Kido S, Ae R, Kosami K, Matsubara Y, Makino N, Sasahara T, Kuwabara M, Aoyama Y, Yashiro M, Yanagawa H, Nakamura Y.

Pediatr Int. 2019 Jun;61(6):539-543. doi: 10.1111/ped.13863. Epub 2019 Jun 18.

PMID:
30980447
4.

Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016.

Makino N, Nakamura Y, Yashiro M, Kosami K, Matsubara Y, Ae R, Aoyama Y, Yanagawa H.

Pediatr Int. 2019 Apr;61(4):397-403. doi: 10.1111/ped.13809. Epub 2019 Apr 16.

PMID:
30786118
5.

Perspectives of non-specialists on the potential to serve as ethics committee members.

Kane C, Takechi K, Chuma M, Nokihara H, Takagai T, Yanagawa H.

J Int Med Res. 2019 May;47(5):1868-1876. doi: 10.1177/0300060518823941. Epub 2019 Jan 24.

6.

The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.

Oki R, Izumi Y, Nodera H, Sato Y, Nokihara H, Kanai K, Sonoo M, Urushitani M, Nishinaka K, Atsuta N, Kohara N, Shimizu T, Kikuchi H, Oda M, Ikeda K, Nagai M, Komai K, Kojima Y, Kuzume D, Isose S, Shimohama S, Abe K, Ito H, Noda K, Ishihara T, Morita M, Shimohata T, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; JETALS.

JMIR Res Protoc. 2018 Dec 21;7(12):e12046. doi: 10.2196/12046.

7.

Relationship between the administration of nicardipine hydrochloride and the development of delirium in patients on mechanical ventilation.

Zamami Y, Kouno Y, Niimura T, Chuma M, Imai T, Mitsui M, Koyama T, Kayano M, Okada N, Hamano H, Goda M, Imanishi M, Takechi K, Horinouchi Y, Kondo Y, Yanagawa H, Kitamura Y, Sendo T, Ujike Y, Ishizawa K.

Pharmazie. 2018 Dec 1;73(12):740-743. doi: 10.1691/ph.2018.8711.

PMID:
30522561
8.

Present Status and Perspectives on Future Roles of Japanese Clinical Research Coordinators.

Yanagawa H, Nokihara H, Yokoi H, Houchi H, Nagai M, Yamashita R, Suganuma N, Hyodo M; Shikoku Collaborative Group for Promotion of Clinical Trials.

J Clin Med Res. 2018 Dec;10(12):877-882. doi: 10.14740/jocmr3602w. Epub 2018 Oct 30.

9.

Prevalence of Vibrio parahaemolyticus in seafood and water environment in the Mekong Delta, Vietnam.

Tran THT, Yanagawa H, Nguyen KT, Hara-Kudo Y, Taniguchi T, Hayashidani H.

J Vet Med Sci. 2018 Nov 23;80(11):1737-1742. doi: 10.1292/jvms.18-0241. Epub 2018 Sep 25.

10.

Development and pharmacist-mediated use of tools for monitoring atypical antipsychotic-induced side effects related to blood glucose levels.

Ishida S, Takechi K, Bando H, Imanishi M, Zamami Y, Chuma M, Yanagawa H, Kirino Y, Nakamura T, Teraoka K, Ishizawa K.

Pharmacoepidemiol Drug Saf. 2018 Dec;27(12):1379-1384. doi: 10.1002/pds.4656. Epub 2018 Sep 17.

PMID:
30221424
11.

Research ethics consultation: an attempt and 5-year experience in a Japanese University Hospital.

Yanagawa H, Katashima R, Sato C, Takechi K, Nokihara H, Kane C, Chuma M, Aoe Y.

BMC Res Notes. 2018 Sep 12;11(1):665. doi: 10.1186/s13104-018-3772-0.

12.

Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database.

Hamano H, Mitsui M, Zamami Y, Takechi K, Nimura T, Okada N, Fukushima K, Imanishi M, Chuma M, Horinouchi Y, Izawa-Ishizawa Y, Kirino Y, Nakamura T, Teraoka K, Ikeda Y, Fujino H, Yanagawa H, Tamaki T, Ishizawa K.

Support Care Cancer. 2019 Mar;27(3):849-856. doi: 10.1007/s00520-018-4367-y. Epub 2018 Jul 31.

PMID:
30062585
13.

The effects of early intravenous immunoglobulin therapy for Kawasaki disease: The 22nd nationwide survey in Japan.

Kuwabara M, Yashiro M, Ae R, Yanagawa H, Nakamura Y.

Int J Cardiol. 2018 Oct 15;269:334-338. doi: 10.1016/j.ijcard.2018.07.092. Epub 2018 Jul 19.

PMID:
30049499
14.

FECAL PROGESTERONE METABOLITES IN POSTPARTUM SIBERIAN FLYING SQUIRRELS.

Shimamoto T, Suzuki KK, Hamada M, Furukawa R, Matsui M, Yanagawa H.

J Zoo Wildl Med. 2018 Mar;49(1):237-241. doi: 10.1638/2016-0273R2.1.

PMID:
29517445
15.

Epidemiological observations of Kawasaki disease in Japan, 2013-2014.

Makino N, Nakamura Y, Yashiro M, Sano T, Ae R, Kosami K, Kojo T, Aoyama Y, Kotani K, Yanagawa H.

Pediatr Int. 2018 Jun;60(6):581-587. doi: 10.1111/ped.13544.

PMID:
29498791
16.

Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy.

Placzek WJ, Yanagawa H, Makita Y, Renfrow MB, Julian BA, Rizk DV, Suzuki Y, Novak J, Suzuki H.

PLoS One. 2018 Jan 11;13(1):e0190967. doi: 10.1371/journal.pone.0190967. eCollection 2018.

17.

Pharmacy Students' Knowledge and Attitude toward Registration Trials and Clinical Research: A Survey in a Japanese University Hospital.

Ise N, Takechi K, Miyamoto T, Ishizawa K, Yanagawa H.

Pharmacy (Basel). 2017 Dec 11;5(4). pii: E67. doi: 10.3390/pharmacy5040067.

18.

Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders.

Takechi K, Yoshioka Y, Kawazoe H, Tanaka M, Takatori S, Kobayashi M, Matsuoka I, Yanagawa H, Zamami Y, Imanishi M, Ishizawa K, Tanaka A, Araki H.

Biol Pharm Bull. 2017;40(10):1775-1778. doi: 10.1248/bpb.b17-00053.

19.

A novel phenylphthalimide derivative, pegylated TC11, improves pharmacokinetic properties and induces apoptosis of high-risk myeloma cells via G2/M cell-cycle arrest.

Aida S, Hozumi M, Ichikawa D, Iida K, Yonemura Y, Tabata N, Yamada T, Matsushita M, Sugai T, Yanagawa H, Hattori Y.

Biochem Biophys Res Commun. 2017 Nov 4;493(1):514-520. doi: 10.1016/j.bbrc.2017.08.159. Epub 2017 Sep 1.

PMID:
28867196
20.

Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.

Takechi K, Yanagawa H, Zamami Y, Ishizawa K, Tanaka A, Araki H.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):672-677. doi: 10.5414/CP203009.

PMID:
28655381
21.

Impact of preoperative ultrasonography findings on the patency rate of vascular access in Japanese hemodialysis patients.

Nakata J, Io H, Watanabe T, Sasaki Y, Makita Y, Aoki T, Yanagawa H, Kanda R, Tomino Y.

Springerplus. 2016 Apr 14;5:462. doi: 10.1186/s40064-016-2082-z. eCollection 2016.

22.

Temporal and geographical clustering of Kawasaki disease in Japan: 2007-2012.

Sano T, Makino N, Aoyama Y, Ae R, Kojo T, Kotani K, Nakamura Y, Yanagawa H.

Pediatr Int. 2016 Nov;58(11):1140-1145. doi: 10.1111/ped.12970. Epub 2016 Jun 21.

PMID:
26940079
23.

PURE mRNA display for in vitro selection of single-chain antibodies.

Nagumo Y, Fujiwara K, Horisawa K, Yanagawa H, Doi N.

J Biochem. 2016 May;159(5):519-26. doi: 10.1093/jb/mvv131. Epub 2015 Dec 28.

PMID:
26711234
24.

Japanese Physicians' Views on Drug Post-Marketing Surveillance.

Maeda K, Katashima R, Ishizawa K, Yanagawa H.

J Clin Med Res. 2015 Dec;7(12):956-60. doi: 10.14740/jocmr2328w. Epub 2015 Oct 23.

25.

Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Konaka K, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Ishizawa K.

Biol Pharm Bull. 2015;38(11):1752-6. doi: 10.1248/bpb.b15-00435.

26.

[Report from 18th Shikoku Chapter Educational Seminar: The significance of detailed clinical history in the differential diagnosis of patients with impaired consciousness].

Yamaguchi H, Bando H, Shintani Y, Yanagawa H, Matsui N, Shigekiyo T, Tanabe M, Takaoka S, Iima T, Oura M, Kita S, Tone S, Noda K, Morizumi S.

Nihon Naika Gakkai Zasshi. 2015 Jul 10;104(7):1495-503. Japanese. No abstract available.

PMID:
26513970
27.

Effects of dietary soy protein on skeletal muscle volume and strength in humans with various physical activities.

Hashimoto R, Sakai A, Murayama M, Ochi A, Abe T, Hirasaka K, Ohno A, Teshima-Kondo S, Yanagawa H, Yasui N, Inatsugi M, Doi D, Takeda M, Mukai R, Terao J, Nikawa T.

J Med Invest. 2015;62(3-4):177-83. doi: 10.2152/jmi.62.177.

28.

Research ethics committees in Japan: A perspective from thirty years of experience at Tokushima University.

Yanagawa H, Katashima R, Takeda N.

J Med Invest. 2015;62(3-4):114-8. doi: 10.2152/jmi.62.114. Review.

29.

Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy.

Yasutake J, Suzuki Y, Suzuki H, Hiura N, Yanagawa H, Makita Y, Kaneko E, Tomino Y.

Nephrol Dial Transplant. 2015 Aug;30(8):1315-21. doi: 10.1093/ndt/gfv221. Epub 2015 Jun 23.

30.

Catalytic subunits of the phosphatase calcineurin interact with NF-κB-inducing kinase (NIK) and attenuate NIK-dependent gene expression.

Shinzawa M, Konno H, Qin J, Akiyama N, Miyauchi M, Ohashi H, Miyamoto-Sato E, Yanagawa H, Akiyama T, Inoue J.

Sci Rep. 2015 Jun 1;5:10758. doi: 10.1038/srep10758.

31.

Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey.

Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H.

J Epidemiol. 2015;25(3):239-45. doi: 10.2188/jea.JE20140089. Epub 2015 Feb 7.

32.

Cardiac lesions and initial laboratory data in Kawasaki disease: a nationwide survey in Japan.

Kuwabara M, Yashiro M, Kotani K, Tsuboi S, Ae R, Nakamura Y, Yanagawa H, Kawasaki T.

J Epidemiol. 2015;25(3):189-93. doi: 10.2188/jea.JE20140128. Epub 2015 Jan 10.

33.

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.

Matsushita M, Ozaki Y, Hasegawa Y, Terada F, Tabata N, Shiheido H, Yanagawa H, Oikawa T, Matsuo K, Du W, Yamada T, Hozumi M, Ichikawa D, Hattori Y.

PLoS One. 2015 Jan 24;10(1):e0116135. doi: 10.1371/journal.pone.0116135. eCollection 2015.

34.

Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer.

Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, Nakamura T, Teraoka K, Kawazoe K, Yanagawa H, Nishioka Y, Minakuchi K, Ishizawa K.

Ann Pharmacother. 2015 Apr;49(4):398-404. doi: 10.1177/1060028014566446. Epub 2015 Jan 6.

PMID:
25565405
35.

Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers.

Suzuki Y, Suzuki H, Makita Y, Takahata A, Takahashi K, Muto M, Sasaki Y, Kelimu A, Matsuzaki K, Yanagawa H, Okazaki K, Tomino Y.

Int J Nephrol Renovasc Dis. 2014 Oct 30;7:409-14. doi: 10.2147/IJNRD.S50513. eCollection 2014. Review.

36.

Structural basis for inhibition of the MDM2:p53 interaction by an optimized MDM2-binding peptide selected with mRNA display.

Nagata T, Shirakawa K, Kobayashi N, Shiheido H, Tabata N, Sakuma-Yonemura Y, Horisawa K, Katahira M, Doi N, Yanagawa H.

PLoS One. 2014 Oct 2;9(10):e109163. doi: 10.1371/journal.pone.0109163. eCollection 2014.

37.

Present status of Japanese ethics committees: a survey in Tokushima Prefecture.

Katashima R, Sato C, Kinoshita S, Kawashima S, Yanagawa H.

J Med Invest. 2014;61(3-4):399-403.

38.

NESmapper: accurate prediction of leucine-rich nuclear export signals using activity-based profiles.

Kosugi S, Yanagawa H, Terauchi R, Tabata S.

PLoS Comput Biol. 2014 Sep 18;10(9):e1003841. doi: 10.1371/journal.pcbi.1003841. eCollection 2014 Sep.

39.

Nurse awareness of clinical research: a survey in a Japanese University Hospital.

Yanagawa H, Takai S, Yoshimaru M, Miyamoto T, Katashima R, Kida K.

BMC Med Res Methodol. 2014 Jul 2;14:85. doi: 10.1186/1471-2288-14-85.

40.

Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.

Satake K, Shimizu Y, Sasaki Y, Yanagawa H, Suzuki H, Suzuki Y, Horikoshi S, Honda S, Shibuya K, Shibuya A, Tomino Y.

BMC Nephrol. 2014 Jun 13;15:89. doi: 10.1186/1471-2369-15-89.

41.

Analysis of transcription factor networks using IVV method.

Ohashi H, Fujimori S, Hirai N, Yanagawa H, Miyamoto-Sato E.

Methods Mol Biol. 2014;1164:15-22. doi: 10.1007/978-1-4939-0805-9_2.

PMID:
24927831
42.

A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases.

Yanagawa H, Suzuki H, Suzuki Y, Kiryluk K, Gharavi AG, Matsuoka K, Makita Y, Julian BA, Novak J, Tomino Y.

PLoS One. 2014 May 23;9(5):e98081. doi: 10.1371/journal.pone.0098081. eCollection 2014.

43.

Mitochondria-nucleus shuttling FK506-binding protein 51 interacts with TRAF proteins and facilitates the RIG-I-like receptor-mediated expression of type I IFN.

Akiyama T, Shiraishi T, Qin J, Konno H, Akiyama N, Shinzawa M, Miyauchi M, Takizawa N, Yanai H, Ohashi H, Miyamoto-Sato E, Yanagawa H, Yong W, Shou W, Inoue J.

PLoS One. 2014 May 1;9(5):e95992. doi: 10.1371/journal.pone.0095992. eCollection 2014.

44.

Serious adverse events and compensation in registration trials: a review of data from a Japanese university hospital.

Watanabe M, Tajima S, Katashima R, Miyamoto T, Yamagami M, Minakuchi K, Yanagawa H.

BMC Res Notes. 2014 Apr 17;7:245. doi: 10.1186/1756-0500-7-245.

45.

A canine case of primary intra-right atrial paraganglioma.

Yanagawa H, Hatai H, Taoda T, Boonsriroj H, Kimitsuki K, Park CH, Oyamada T.

J Vet Med Sci. 2014 Jul;76(7):1051-3. Epub 2014 Mar 26.

46.

Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy.

Nakata J, Suzuki Y, Suzuki H, Sato D, Kano T, Yanagawa H, Matsuzaki K, Horikoshi S, Novak J, Tomino Y.

PLoS One. 2014 Feb 21;9(2):e89707. doi: 10.1371/journal.pone.0089707. eCollection 2014.

47.

Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy.

Suzuki Y, Matsuzaki K, Suzuki H, Okazaki K, Yanagawa H, Ieiri N, Sato M, Sato T, Taguma Y, Matsuoka J, Horikoshi S, Novak J, Hotta O, Tomino Y.

Clin Exp Nephrol. 2014 Oct;18(5):770-7. doi: 10.1007/s10157-013-0921-6. Epub 2014 Jan 30.

48.

MIP-2A is a novel target of an anilinoquinazoline derivative for inhibition of tumour cell proliferation.

Tokunaga M, Shiheido H, Tabata N, Sakuma-Yonemura Y, Takashima H, Horisawa K, Doi N, Yanagawa H.

PLoS One. 2013 Sep 30;8(9):e76774. doi: 10.1371/journal.pone.0076774. eCollection 2013.

49.

Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009.

Nakamura Y, Aso E, Yashiro M, Tsuboi S, Kojo T, Aoyama Y, Kotani K, Uehara R, Yanagawa H.

J Epidemiol. 2013;23(6):429-34. Epub 2013 Sep 14.

50.

Participant preferences for the provision of registration trials results.

Tajima S, Akaishi A, Miyamoto T, Katashima R, Nakai K, Mitsui T, Yanagawa H.

J Clin Med Res. 2013 Oct;5(5):401-6. doi: 10.4021/jocmr1494w. Epub 2013 Aug 5.

Supplemental Content

Loading ...
Support Center